Literature DB >> 29201207

Clinical significance of novel biomarker NGAL in early diagnosis of acute renal injury.

Jinghua Zhang1, Jianle Han1, Jinrui Liu1, Bing Liang1, Xiaobo Wang1, Changan Wang1.   

Abstract

The present study investigated the clinical significance of the novel biomarker neutrophil gelatinase-associated lipocalin (NGAL) for the early diagnosis of acute renal injury (AKI). Thirty-eight critically ill patients with acute renal injury treated at Zhengzhou No. 7 People's Hospital between December 2015 and November 2016 served as the AKI group (observation group). At the same time, 38 critically ill patients without acute renal injury were also selected as the non-AKI group (control group). Serum NGAL and creatinine (SCr) levels were measured by enzyme-linked immunosorbent assay (ELISA) at 2, 8, 12 and 24 h post-operation, whereas particle-enhanced turbidimetric immunoassay (PETIA) was used to quantify the levels of cysteine protease inhibitor cystatin C (CysC) in serum at 2, 8, 12 and 24 h post-operation. The correlations between indicators were also analyzed, with ROC curves used to evaluate the diagnostic values of NGAL, SCr and CysC in AKI. No significant differences in SCr levels were found between the two groups at different time-points after operation (P>0.05), but NGAL and CysC levels in the observation group were significantly higher than in the control group (P<0.05). Pearson correlation coefficient analysis showed NGAL and CysC were positively correlated with Scr levels. For NGAL in early diagnosis, the area under the AKI curve was 0.904, the sensitivity was 90.2% and the specificity was 89.5%; for CysC in early diagnosis, the area under the AKI curve was 0.806, the sensitivity was 79.2% and the specificity was 78.5%; for SCr in early diagnosis, the area under the AKI curve was 0.634, the sensitivity was 64.2% and the specificity was 62.5%. Therefore, NGAL demonstrated a satisfactory early predictive value for AKI and can be used as a biomarker for early AKI diagnosis.

Entities:  

Keywords:  acute renal injury; cysteine protease inhibitor cystatin C; neutrophil gelatinase-associated lipocalin; serum creatinine

Year:  2017        PMID: 29201207      PMCID: PMC5704279          DOI: 10.3892/etm.2017.5150

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


Introduction

Acute renal injury (AKI), also known as acute renal failure, refers to the clinical syndrome of a sudden decline in renal function during the first 3 months of a disease course (1). AKI can be caused by a variety of factors, with clinical manifestations including fluid and electrolyte balance and acid and alkaline balance disorders as well as azotemia (2). AKI incidence in critically ill patients is high (up to 30–50%), and AKI severity is positively correlated with patient mortality, with AKI is one of the leading causes of death in critically ill patients (3). AKI can increase the burden of disease and the treatment costs of critically ill patients. At present, the pathophysiological mechanism of AKI is not yet fully understood, so improving treatment methods is a challenge. Therefore, AKI has become one of the most difficult medical problems present throughout the world (4,5). SCr is often used as a diagnostic index for AKI, but SCr levels are affected by many factors (blood volume, muscle mass and protein intake), leading to its uncertain association with acute renal cell injury. As such, SCr cannot be used to accurately and timely reflect the occurrence of AKI (6). Early detection and timely treatment is the key for the treatment of AKI, so the identification of novel biomarkers of AKI for early diagnosis is particularly important. As a member of lipocalin superfamily, NGAL was considered to be one of the ideal and important biomarkers in the diagnosis of AKI (7). CysC is a member of the cysteine protease inhibitor superfamily and is frequently used as a marker for the diagnosis of AKI. In this study, we examined and analyzed NGAL levels in critically ill patients after surgery. The present study provided a theoretical basis for the early diagnosis of AKI.

Materials and methods

General information

Thirty-eight critically ill patients with acute renal injury treated at Zhengzhou No. 7 People's Hospital between December 2015 and November 2016 were selected to serve as AKI group (observation group). At the same time, 38 critically ill patients without acute renal injury were selected as the non-AKI group (control group). Inclusion criteria were as follows: i) critically ill patients with surgical treatment; ii) ICU stay ≥24 h; iii) patients provided informed consent. Exclusion criteria were as follows: i) patients had received nephrotoxic drugs within the week prior to selection; ii) patients had received conventional dialysis before admission; iii) patients with heart failure and malignant tumors. There were no significant differences in general information parameters between the two groups (P>0.05; Table I). The study was approved by the Ethics Committee of Zhengzhou No. 7 People's Hospital.
Table I.

General patient information.

ItemsObservation group (n=38)Control group (n=38)t/χ2P-value
Sex (male/female)21/1720/180.0460.829
Age range (years)40–7535–75
Average age (years)48.76±7.4849.07±7.860.1760.861
MAP (mmHg)96.87±12.3797.35±11.580.1750.862
WBC (109/l)16.06±5.9315.84±5.740.1640.869
Serum BUN (mmol/n)29.03±5.8328.14±5.350.6930.490
Type of damage (n, %)
  Acute tubular necrosis15 (39.47)16 (42.11)0.0470.827
  Acute glomerular injury14 (36.84)15 (39.47)0.0530.818
  Acute interstitial nephritis9 (23.68)7 (18.42)0.0760.781

Experimental methods

Experimental equipment and reagents

Main equipment consisted of a microplate reader (Jiangsu Potebio Biotechnology Co., Ltd., Jiangsu, China), automatic biochemical instrument (Precise, Beijing, China), centrifuge (Beijing Guangan Medical Equipment Factory), pipettes (Dragon Laboratory Instruments Ltd., Beijing, China), EP tubes and centrifuge tubes (Haimen Innovative Experimental Equipment Factory, Jiangsu, China). Experimental reagents consisted of NGAL ELISA kits (R&D Systems, Inc., Minneapolis, MN, USA), CysC kits (Beijing Strong Biotechnologies, Inc., Beijing, China) and SCr kits (BioSino, Beijing, China).

Specimen collection

Blood samples were extracted from the radial artery of all patients at 2, 8, 12 and 24 h post-operation. The blood samples were centrifuged for 5 min, and the supernatant was transferred into EP tubes and kept at −80°C for storage.

Indicator detection

NGAL and Scr levels were detected using ELISA according to the manufacturers instructions. In brief: i) blood stored at −80°C was thawed at room temperature (20°C); ii) samples and standards were diluted (dilution ratio 1:5) and transferred to the plate; iii) samples were incubated in the plate for 30 min at 37°C and then washed with phosphate-buffered saline (PBS) 5 times for 15 sec for each time; iv) enzyme-conjugated reagent (50 µl) was added and incubated at 37°C for 30 min, followed by four 15-sec washes; v) color developer A and B were added and the samples were incubated at room temperature in the dark for 15 min. The termination solution was then added, and the OD value at 450 nm was measured using a microplate reader within 15 min. These readings were used to calculate NGAL and Scr levels. CysC levels were detected using PETIA, under the principle that serum CysC can bind to latex particles coated with goat anti-human CysC polyclonal antibodies (dilution 1:500; cat. no. PD-RM-0006-M0001; Biomart, Wuhan, China), resulting in increased turbidity at 600 nm proportional to CysC levels. The main parameters of the assay were as follows: main wavelength, 600 nm; reaction methods, point end assay; reaction direction, positive; temperature, 37°C. The difference in OD value of the calibration solution (OD value at 5 min later - OD value at 1 min later) was calculated, and an absorbance-concentration curve for the calibration solution was established. The difference in sample OD value was then calculated and CysC level was calculated according to the absorbance-concentration curve.

Evaluation criteria

Serum NGAL and Scr levels were measured by ELISA at 2, 8, 12 and 24 h post-operation and serum CysC levels were measured by PETIA at the same time-points.

Statistical analysis

Data were processed using the SPSS 19.0 (SPSS, Inc., Chicago, IL, USA) software. Measurement data were expressed as mean ± standard deviation (false) and comparisons between groups were performed using the t-test. Measurement data were expressed by ratio and comparison between the groups were performed using χ2 test. Pearson correlation coefficient analysis was carried out for correlation analysis. Diagnostic value was analyzed by ROC curve. P<0.05 was considered to be statistically significant.

Results

Serum NGAL levels

The serum NGAL level in the observation group was significantly higher than in the control group at 2, 8, 12 and 24 h after operation (P<0.05; Table II).
Table II.

NGAL level comparison (ng/ml).

GroupCases2 h8 h12 h24 h
Observation3881.78±3.4883.93±3.2385.29±3.4889.29±3.48
Control3823.04±3.9821.05±3.3218.06±3.5917.64±3.59
t-value68.94183.68382.88988.339
P-value<0.001<0.001<0.001<0.001

Serum SCr levels

No significant difference in SCr level was found between observation and control groups at 2, 8, 12 and 24 h after operation (P<0.05; Table III).
Table III.

SCr level comparison (µmol/l).

GroupCases2 h8 h12 h24 h
Observation3872.18±3.5470.84±3.2873.87±3.2578.78±3.74
Control3872.05±3.7271.03±3.6274.25±3.1779.04±3.69
t-value0.1560.2400.5160.305
P-value0.8760.8110.6070.761

Serum CysC levels

The serum CysC level in the observation group was significantly higher than in the control group at 2, 8, 12 and 24 h after operation (P<0.05; Table IV).
Table IV.

CysC level comparison (mg/l).

GroupCases2 h8 h12 h24 h
Observation384.08±0.434.23±0.284.39±0.384.59±0.47
Control382.83±0.782.57±0.371.73±0.491.03±0.52
t-value8.65122.05426.44431.309
P-value<0.001<0.001<0.001<0.001

Correlation analysis between NGAL, CysC and Scr

Pearson correlation coefficient analysis showed that NGAL and CysC levels were positively correlated with SCr levels (P<0.05; Table V and Figs. 1 and 2).
Table V.

Correlation between NGAL and CysC levels and SCr level.

IndicationrP-value
NGAL0.5180.013
CysC0.5010.027
Figure 1.

Correlation between NGAL and SCr levels. Pearson correlation coefficient analysis showed that NGAL levels were positively correlated with SCr levels (P<0.05).

Figure 2.

Correlation between NGAL and CysC levels. Pearson correlation coefficient analysis showed that NGAL levels were positively correlated with CysC levels (P<0.05).

Comparison of NGAL, CysC and SCr for the early diagnosis of AKI

The potential of NGAL, CysC and SCr for use as an early diagnostic marker of AKI was evaluated. For NGAL, the area under the AKI curve was 0.904, the sensitivity was 90.2% and the specificity was 89.5%; for CysC, the area under the AKI curve was 0.806, the sensitivity was 79.2% and the specificity was 78.5%; for Scr, the area under the AKI curve was 0.634, the sensitivity was 64.2% and the specificity was 62.5% (Fig. 3).
Figure 3.

Comparison of NGAL, CysC and Scr for early diagnosis of AKI. The area below the AKI curve of NGAL for early diagnosis of AKI was larger than that of CysC, and the area below the AKI curve of CysC for early diagnosis of AKI was larger than that of SCr.

Discussion

AKI is a new concept proposed by the International Renal Disease and Emergency Medicine community to replace the term ‘acute renal failure’. Infectious diseases are the main causes of AKI, and other causes may include cardiogenic shock, hypovolemia, septic shock and major surgery. AKI is common for critically ill patients in the ICU. The mortality rate of AKI is high and AKI is also an independent risk factor for death in critically ill patients (8). The renal function of AKI patients can be significantly reduced within a short time, and the resultant inability to excrete metabolites reduces the stability of the internal environment. The diagnostic criteria used to identify AKI are: sudden changes in renal structure or function within 48 h identified by imaging, or hematuria during routine examination found within 3 months, with an increase in SCr content greater than 26.4 µmol/l or 50% of the base value; urine output below 0.5 ml/(kg·h) for more than 6 h, but not including patients with dehydration and obstructive nephropathy (9). Compared with the term ‘acute renal failure’, the term AKI covers a wider range, including renal damage from slight changes in renal function to final renal function loss. AKI can accurately reflect the developmental nature of nephropathy (10). Although the incidence of AKI is high, the awareness rate is generally low. Early symptoms of AKI are not typical, and this, coupled with the fact that diagnoses are affected by a variety of factors, results in low diagnostic sensitivity. This in turn delays diagnosis and increases mortality in critically ill patients (11). Most AKI cases are reversible, and early diagnosis and treatment can prevent the development of renal failure. Therefore, diagnosis and treatment are keys in reducing the mortality rate in critically ill patients with AKI (12). Urine output and changes in SCr levels are usually used to reflect changes in glomerular filtration rate and renal function decline in order to provide a basis for the diagnosis of AKI. Renal tubular damage can destroy the renal hypertonic environment and reduce the ability to concentrate urine, resulting in non-oliguric nephropathy (13). In addition, urine output, which is affected by diuretics and bladder capacity, cannot reflect renal function in real-time. Therefore, for the diagnosis of AKI, urine output and SCr levels cannot properly reflect renal injury. This misses the optimal time-point for treatment and increases patient pain and systemic economic burden (14). The results of this study showed that there was no significant difference in serum SCr level between the two groups at 2, 8, 12 and 24 h after operation (P>0.05). This was because serum SCr level is affected by nutritional status, muscle metabolism, and preoperative medication. Renal compensatory and reserve capacity is strong under normal conditions. SCr levels can only be increased slightly when the glomerular filtration rate is reduced by 50% or more. In addition, SCr accumulation takes time, and SCr levels cannot reach a stable state within a short period (6). Therefore, SCr cannot be used as a marker to accurately reflect short-term changes in renal function. NGAL is a member of lipocalin superfamily with a small molecular weight of only 25 kDa (15). NGAL was first found in human neutrophils. NGAL is very stable, so it can be easily detected in serum. Under normal conditions, low NGAL expression levels can be detected in a variety of tissues (lung, kidney, large intestine and stomach). High expression levels of NGAL can be induced by cell apoptosis after epithelial cell damage (16). The results of this study showed that serum NGAL levels in the observation group were significantly higher than in the control group at 2, 8, 12 and 24 h after operation (P<0.05). A possible mechanism for this phenomenon may be that various factors stimulated renal tubular epithelial cells, leading to increased NGAL expression. NGAL can be absorbed by renal epithelial cells to regulate the expression of apoptosis-related proteins, which in turn promotes cell maturation and induces granulocyte apoptosis (16). CysC, a member of the cysteine protease inhibitor superfamily, is a type of non-glycosylated alkaline protein secreted by karyocytes. CysC can be synthesized at a very stable rate and released into the circulation. After complete glomerular filtration, CysC will be uptaken and degraded by nearby tubule epithelial cells. Therefore, serum CysC levels can precisely reflect the glomerular filtration rate. As such, CysC can be an ideal marker for the diagnosis of AKI (17–19). Under normal conditions, CysC levels are low. However, CysC levels can significantly increase after renal tubular injury (20). The results of this study showed that the serum CysC levels in the observation group were significantly higher than in the control group at 2, 8, 12,0 and 24 h after operation (P<0.05), indicating that internal environment of the patients was altered after AKI. Relevant studies have confirmed that increased NGAL and CysC levels appeared 24 to 48 h prior to SCr level increases in the diagnosis of AKI (21). In the present study, we found that for NGAL in early diagnosis, the area under the AKI curve was 0.904, the sensitivity was 90.2% and the specificity was 89.5%; for CysC in early diagnosis, the area under the AKI curve was 0.806, the sensitivity was 79.2% and the specificity was 78.5%; for SCr in early diagnosis, the area under the AKI curve was 0.634, the sensitivity was 64.2% and the specificity was 62.5%. Our findings were consistent with previous studies. In addition, the sensitivity and specificity of NGAL were higher than those of CysC and SCr for the detection of AKI. The results also showed that the levels of NGAL and CysC were positively correlated with SCr levels, indicating that the increased expression of NGAL and CysC were consistent with the upregulation of SCr expression. In summary, evaluating NGAL levels in critically ill patients may improve the early detection of AKI and facilitate early treatment and improve prognosis.
  20 in total

1.  Can admission serum cystatin C level be an early marker subclinical acute kidney injury in critical care patients?

Authors:  Ümmügülsüm Gaygısız; Müge Aydoğdu; Melike Badoğlu; Nazlıhan Boyacı; Zuhal Güllü; Gül Gürsel
Journal:  Scand J Clin Lab Invest       Date:  2016-01-15       Impact factor: 1.713

2.  Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?

Authors:  Jeremiah R Brown; John F Robb; Clay A Block; Anton C Schoolwerth; Aaron V Kaplan; Gerald T O'Connor; Richard J Solomon; David J Malenka
Journal:  Circ Cardiovasc Interv       Date:  2010-06-29       Impact factor: 6.546

3.  Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study.

Authors:  Eric A J Hoste; Sean M Bagshaw; Rinaldo Bellomo; Cynthia M Cely; Roos Colman; Dinna N Cruz; Kyriakos Edipidis; Lui G Forni; Charles D Gomersall; Deepak Govil; Patrick M Honoré; Olivier Joannes-Boyau; Michael Joannidis; Anna-Maija Korhonen; Athina Lavrentieva; Ravindra L Mehta; Paul Palevsky; Eric Roessler; Claudio Ronco; Shigehiko Uchino; Jorge A Vazquez; Erick Vidal Andrade; Steve Webb; John A Kellum
Journal:  Intensive Care Med       Date:  2015-07-11       Impact factor: 17.440

4.  Cystatin C in acute kidney injury diagnosis: early biomarker or alternative to serum creatinine?

Authors:  Paola Lagos-Arevalo; Ana Palijan; Laura Vertullo; Prasad Devarajan; Michael R Bennett; Venkata Sabbisetti; Joseph V Bonventre; Qing Ma; Ronald D Gottesman; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2014-12-05       Impact factor: 3.714

Review 5.  Acute Kidney Injury in Cirrhosis.

Authors:  Constantine J Karvellas; Francois Durand; Mitra K Nadim
Journal:  Crit Care Clin       Date:  2015-08-05       Impact factor: 3.598

6.  Plasma NGAL similarly predicts acute kidney injury in sepsis and nonsepsis.

Authors:  Hilde R H de Geus; Michiel G Betjes; Ron van Schaick; Johan A B J Groeneveld
Journal:  Biomark Med       Date:  2013-06       Impact factor: 2.851

7.  Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial.

Authors:  Paul Young; Michael Bailey; Richard Beasley; Seton Henderson; Diane Mackle; Colin McArthur; Shay McGuinness; Jan Mehrtens; John Myburgh; Alex Psirides; Sumeet Reddy; Rinaldo Bellomo
Journal:  JAMA       Date:  2015-10-27       Impact factor: 56.272

8.  Serum Cystatin C for the Diagnosis of Acute Kidney Injury in Patients Admitted in the Emergency Department.

Authors:  Cristina Bongiovanni; Laura Magrini; Gerardo Salerno; Chiara Serena Gori; Patrizia Cardelli; Mina Hur; Marco Buggi; Salvatore Di Somma
Journal:  Dis Markers       Date:  2015-06-15       Impact factor: 3.434

9.  Early serum creatinine accurately predicts acute kidney injury post cardiac surgery.

Authors:  Keren Grynberg; Kevan R Polkinghorne; Sharon Ford; Fiona Stenning; Thomas E Lew; Jonathan A Barrett; Shaun A Summers
Journal:  BMC Nephrol       Date:  2017-03-16       Impact factor: 2.388

Review 10.  The growth of acute kidney injury: a rising tide or just closer attention to detail?

Authors:  Edward D Siew; Andrew Davenport
Journal:  Kidney Int       Date:  2014-09-17       Impact factor: 10.612

View more
  8 in total

1.  Neutrophil Gelatinase-Associated Lipocalin Acts as a Robust Early Diagnostic Marker for Renal Replacement Therapy in Patients with Russell's Viper Bite-Induced Acute Kidney Injuries.

Authors:  Subramanian Senthilkumaran; Ketan Patel; Anika Salim; Pradeep Vijayakumar; Harry F Williams; Rajendran Vaiyapuri; Ravi Savania; Namasivayam Elangovan; Ponniah Thirumalaikolundusubramanian; M Fazil Baksh; Sakthivel Vaiyapuri
Journal:  Toxins (Basel)       Date:  2021-11-12       Impact factor: 4.546

Review 2.  The Perspectives of Biomarkers in Predicting the Survival of the Renal Graft.

Authors:  Paul Luchian Aldea; Andreea Liana Rachisan; Bogdan Ioan Stanciu; Andrei Picos; Alina Monica Picos; Dan Ioan Delean; Ramona Stroescu; Magdalena Iuliana Starcea; Cristina Maria Borzan; Florin Ioan Elec
Journal:  Front Pediatr       Date:  2022-06-03       Impact factor: 3.569

3.  Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials.

Authors:  Xiaoqian Hong; Huihui Yan; Fuan Xie; Kaiyu Wang; Qiang Wang; Huijuan Huang; Kunrong Yang; Suhong Huang; Tingting Zhao; Junkai Wang; Yunyun Chen; Kuancan Liu; Xiaopeng Lan
Journal:  J Transl Med       Date:  2019-06-18       Impact factor: 5.531

4.  Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus.

Authors:  William A Figgett; Katherine Monaghan; Milica Ng; Monther Alhamdoosh; Eugene Maraskovsky; Nicholas J Wilson; Alberta Y Hoi; Eric F Morand; Fabienne Mackay
Journal:  Clin Transl Immunology       Date:  2019-12-12

5.  Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models.

Authors:  Benjamin Bonnard; Ernesto Martínez-Martínez; Natalia López-Andrés; Frédéric Jaisser; Amaya Fernández-Celis; Marie Pieronne-Deperrois; Quoc-Tuan Do; Isbaal Ramos; Patrick Rossignol; Faiez Zannad; Paul Mulder; Antoine Ouvrard-Pascaud
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

6.  Small Extracellular Vesicles Propagate the Inflammatory Response After Trauma.

Authors:  Tanja Seibold; Jonathan Schönfelder; Florian Weeber; André Lechel; Milena Armacki; Mareike Waldenmaier; Christoph Wille; Annette Palmer; Rebecca Halbgebauer; Ebru Karasu; Markus Huber-Lang; Miriam Kalbitz; Peter Radermacher; Stephan Paschke; Thomas Seufferlein; Tim Eiseler
Journal:  Adv Sci (Weinh)       Date:  2021-10-28       Impact factor: 16.806

7.  Fasting Intervention for Children With Unilateral Renal Tumors to Reduce Toxicity.

Authors:  Christiaan A J Oudmaijer; Winnie M C van den Boogaard; Daphne S J Komninos; Emma J Verwaaijen; Hanneke M van Santen; Marc R Lilien; Jan H J Hoeijmakers; Marc H W Wijnen; Marry M van den Heuvel-Eibrink; Wilbert P Vermeij
Journal:  Front Pediatr       Date:  2022-01-27       Impact factor: 3.418

8.  Is neutrophil gelatinase-associated lipocalin a good diagnostic marker for renal injury in asphyxiated preterm infants?

Authors:  Jing-Jing Pan; Zhong-Yi Sun; Xiao-Yu Zhou; Yu-Hua Hu; Rui Cheng; Xiao-Qing Chen; Yang Yang
Journal:  J Res Med Sci       Date:  2018-10-26       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.